August 13, 2025Neuro-Oncology65 citationsOpen Access
Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions
View Full Paper
Key Points
- Glioblastoma is the most common malignant brain tumor, with high rates of morbidity and mortality.
- The World Health Organization's recent classification aids in predicting outcomes and guides treatment strategies.
- Current therapies include immunotherapies and targeted molecular therapies, focusing on improving patient survival.
- Research challenges persist, indicating the need for ongoing clinical trials to evaluate novel therapies effectively.
Abstract
Glioblastoma is the most common type of malignant primary brain tumor and a major cause of morbidity and mortality. In 2021 the World Health Organization updated the classification of Central Nervous System (CNS) tumors to restrict glioblastomas to isocitrate dehydrogenase-wildtype (IDHwt) tumors, improving understanding of the prognosis and optimal therapy for these tumors. This revision also enables more homogeneous populations of patients to be enrolled into clinical trials, facilitating the evaluation of novel therapies. In this updated consensus review from the Society for Neuro-Oncology (SNO) and the European Association of Neuro-Oncology (EANO), the current management of patients with glioblastoma is discussed. In addition, novel therapies such as immunotherapies, viral therapies, targeted molecular therapies, theranostics and antibody-drug conjugates will be reviewed, as well as the current challenges and future directions for research.
Cite This Study
Wen et al. (2025) studied this question.